Optimized 5‐HT <sub>2b</sub> inhibitors for neuropsychiatric syndromes with cognitive dysfunction
A new highly selective 5-HT<sub>2b</sub>R antagonist, MW073, is described and used as a reference standard.MW073 attenuates synaptic and behavioral dysfunctions an animal models of neuropsychatric syndromes.Risperidone is a dose dependent inhibitor of 5-HT<sub>2b</sub>R activity and arrestin recruitment.
Authors
- Joshua J. Ziarek (ORCID: https://orcid.org/0000-0002-3740-9999)
- Agnieszka Staniszewski
- Elentina K. Argyrousi (ORCID: https://orcid.org/0000-0003-3716-807X)
- Ottavio Arancio (ORCID: https://orcid.org/0000-0001-6335-164X)
- Erica Acquarone (ORCID: https://orcid.org/0000-0002-3266-8115)
- Asuka Inoue (ORCID: https://orcid.org/0000-0003-0805-4049)
- Saktimayee M. Roy (ORCID: https://orcid.org/0000-0001-9096-0491)
- Hong Zhang (ORCID: https://orcid.org/0000-0003-4943-1859)
- D. Martin Watterson (ORCID: https://orcid.org/0000-0001-7605-5866)
Institutions
- Northwestern University (US)
- Tohoku University (JP)
- Kyoto University (JP)
- Kyoto Pharmaceutical University (JP)
- Institute on Aging (US)
- Columbia University (US)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/trc2.70073
- Citations
- 1
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Japan Agency for Medical Research and Development
- National Institutes of Health
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency